转移性去势抵抗性前列腺癌患者接受连续周期177Lu-PSMA I&T治疗后生活质量改善
本回顾性分析纳入60例转移性去势抵抗性前列腺癌(mCRPC)患者,采用欧洲癌症研究与治疗组织核心生活质量问卷评估其接受连续周期177Lu-PSMA放射性配体治疗期间的健康相关生活质量。结果显示,整体健康状况、角色功能、情绪功能在第2和第4治疗周期显著改善,疲乏和疼痛显著减轻,其他生活质量维度大多保持稳定,仅研究结束时疲乏恶化;因疾病进展早期终止治疗的患者生活质量呈一致性下降。
要点
- 整体健康状况在第2和第4周期显著改善(P=0.014和P=0.039)。
- 疲乏和疼痛在第2和第4周期较基线显著减轻。
- 早期终止治疗者生活质量呈一致性下降。
核心结论
- mCRPC患者在接受177Lu-PSMA放射性配体治疗过程中健康相关生活质量显著改善。
- 因疾病进展早期终止治疗的患者生活质量呈一致性下降。
研究设计与样本
- 本回顾性分析共纳入60例mCRPC患者。
- 采用欧洲癌症研究与治疗组织核心生活质量问卷,在基线、每治疗周期前至第6周期、以及第2和第4周期后PSMA配体PET/CT扫描时完成评估。
主要发现
- 整体健康状况在第2和第4治疗周期显著改善(P=0.014和P=0.039)。
- 角色功能在第2和第4治疗周期显著改善(P=0.045和P=0.048),情绪功能在第2和第4治疗周期显著改善(P=0.035和P=0.007)。
- 疼痛在第2和第4治疗周期较基线显著减轻(P=0.035和P=0.034),疲乏在第2和第4治疗周期较基线显著减轻(P=0.042和P=0.041)。
- 其他生活质量方面虽未显著改善但随时间保持稳定,例外为研究结束时疲乏恶化(P=0.014)和第2治疗周期呼吸困难减轻(P=0.012)。
- 早期终止治疗的患者生活质量呈一致性下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this retrospective analysis was to evaluate health-related quality of life (HRQoL) for patients with metastatic castration-resistant prostate cancer (mCRPC) receiving consecutive cycles of 177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using the reliable and validated European Organisation for Research and Treatment of Cancer core quality-of-life (QoL) questionnaire. In addition, differences in HRQoL between patients with early discontinuation of treatment because of disease progression and patients who were defined as eligible for treatment continuation were analyzed. Methods: In total, 60 mCRPC patients were included in this analysis. The European Organisation for Research and Treatment of Cancer core QoL questionnaire was completed at baseline, before each treatment cycle up to the sixth treatment cycle, and at the time of PSMA-ligand PET/CT scans after the second and fourth treatment cycles. QoL assessment included global health status, functional scales, and symptom burden during treatment. Results: Global health was significantly improved at the second and fourth cycles of 177Lu-PSMA RLT (P = 0.014 and P = 0.039, respectively). In line with this, role and emotional functioning showed significant improvements at the second and fourth treatment cycles (role functioning, P = 0.045 and P = 0.048, respectively, and emotional functioning, P = 0.035 and P = 0.007, respectively). In addition, compared with baseline, fatigue and pain were significantly alleviated at the second and fourth treatment cycles (pain, P = 0.035 and P = 0.034, respectively, and fatigue, P = 0.042 and P = 0.041, respectively). Other aspects of HRQoL, even if not significantly improved, remained stable over time, except for deterioration of fatigue at the study's end (P = 0.014) and reduction of dyspnea at the second treatment cycle (P = 0.012). Patients with early discontinuation of treatment showed a concordant decline in HRQoL. Conclusion: mCRPC patients showed significant improvement in HRQoL in the course of treatment with 177Lu-PSMA RLT. Furthermore, patients with early discontinuation of treatment showed an analogous decline in HRQoL.
引用
- Karimzadeh A, Soeiro P, Feuerecker B, et al. Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T. J Nucl Med. 2023. PMID: 37678925. doi:10.2967/jnumed.123.265878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。